Adipotide and Cagrilintide Interaction: Monitor | Peptide Database

Join others researching Tadalafil — share findings, ask questions, and learn from real experiences Tadalafil is a long-acting PDE5 inhibitor FDA-approved for erectile dysfunction (ED), benign prostatic hyperplasia (BPH), and pulmonary arterial hypertension (PAH). Its extended half-life of approximately 17.5 hours provides a therapeutic window of up to 36 hours, earning it the nickname 'the weekend pill.' Unlike shorter-acting PDE5 inhibitors, tadalafil is uniquely suited for daily low-dose use (2.5-5mg), which maintains steady-state plasma levels and allows for spontaneous sexual activity without timing constraints. Originally developed by ICOS Corporation and marketed by Eli Lilly as Cialis, tadalafil received FDA approval in 2003 for ED and has since become one of the most widely prescribed medications in its class. Beyond sexual health, tadalafil has gained attention for its cardiovascular and hemodynamic benefits, including improved endothelial function, reduced blood pressure, and enhanced exercise capacity. Tadalafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in smooth muscle tissue. During sexual stimulation, nitric oxide (NO) is released in the corpus cavernosum, activating guanylate cyclase and increasing cGMP levels. Elevated cGMP causes smooth muscle relaxation in penile arteries and the corpus cavernosum, facilitating increased blood flow and erection. By blocking PDE5, tadalafil prolongs and amplifies this cGMP-mediated vasodilatory signaling cascade. PDE5 is also expressed in pulmonary vasculature, prostatic smooth muscle, and the bladder neck, which accounts for tadalafil's therapeutic effects in PAH and BPH/LUTS. Tadalafil has high selectivity for PDE5 over PDE6 (the retinal isoform), which contributes to its lower incidence of visual disturbances compared to sildenafil.

Protects blood vessels from age-related deterioration through gene expression regulation. Limits development of atherosclerotic plaques in blood vessels. Decreases endothelial dysfunction that contributes to cardiovascular disease. Regulates sirtuin 1 levels, mimicking some benefits of calorie restriction. Enhances mesenchymal stem cell proliferation and reduces senescence. Reverses senescence-associated secretory phenotype in aging cells.